← Back to Home

Novo Nordisk partners with Orbis to develop oral macrocycles in deal worth up to $1.4 billion

The partnership aims to make treatments that currently require injections potentially available in oral form. Orbis uses generative AI and automated synthesis to identify candidate molecules, but the absorption evidence disclosed so far remains preclinical.

By SURL BioNews

A drug’s ability to bind to a disease target does not mean it will also work when swallowed. Getting molecules into the bloodstream after oral administration is a major challenge in drug design. Novo Nordisk and Orbis Medicines announced a partnership on September 17, 2026, to seek new oral medicines for cardiometabolic diseases using AI-assisted macrocycle design.

The multi-target drug discovery and licensing agreement includes up to $1.4 billion in combined upfront, development and commercial milestone payments, plus tiered royalties on future product sales. Novo Nordisk will also make a strategic investment in Orbis. Latham & Watkins, the law firm representing Novo Nordisk, confirmed the deal structure. According to Reuters, the companies disclosed neither the investment amount nor a breakdown of the payments, so the $1.4 billion does not represent funding already received.

The partnership centers on macrocycles, molecules with ring-shaped structures. These molecules may be able to act on targets that are difficult for conventional small-molecule drugs to address, but oral absorption and other requirements for becoming viable drugs have long constrained their development. Orbis hopes to expand the scope of oral treatments, including by exploring targets currently addressed by injectable drugs. The partnership announcement has not identified specific targets or drug candidates.

Orbis’s nGen platform connects generative AI, automated chemical synthesis and experimental data: models propose molecular designs, the laboratory synthesizes and tests them, and the results are fed back into the models. The company says the platform uses its own macrocycle data to improve properties such as oral bioavailability and cell membrane permeability simultaneously. AI’s role here is to help search for molecular structures that meet multiple requirements.

The more concrete indication of absorption disclosed so far comes from comments Orbis CEO Morten Graugaard made in an interview with Reuters: macrocycles synthesized by the company achieved oral bioavailability of up to 18% in preclinical studies. This measure reflects how much of an oral dose reaches systemic circulation. It cannot be interpreted as a treatment success rate or used to directly estimate the dose required in humans or its efficacy.

The report did not provide the species, number of molecules, doses or full experimental conditions behind the 18% result, nor did it confirm that the data came from drug candidates involved in this partnership. The company’s announcement did not disclose the detailed composition of the model’s dataset or results from independent validation. The available information therefore supports the platform’s potential for exploration; multiple validation steps remain before any specific drug can be confirmed safe and effective for use in humans.

For Novo Nordisk, the agreement adds a technological approach to exploring oral medicines for cardiometabolic diseases. For Orbis, it offers an opportunity to move its molecular design platform toward concrete development programs. The most consequential developments ahead will be data on candidate molecules’ absorption, efficacy and safety, and whether those findings can support advancement into human trials.

References

  1. thepharmaletter.com
  2. Orbis Medicines
  3. Reuters via Euronext
  4. Latham & Watkins